218 related articles for article (PubMed ID: 21504249)
1. Sitafloxacin: in bacterial infections.
Keating GM
Drugs; 2011 Apr; 71(6):731-44. PubMed ID: 21504249
[TBL] [Abstract][Full Text] [Related]
2. Sitafloxacin hydrate for bacterial infections.
Anderson DL
Drugs Today (Barc); 2008 Jul; 44(7):489-501. PubMed ID: 18806900
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China.
Wu S; Yang Y; Guo Y; Yin D; Zheng Y; Han R; Ding L; Zhu D; Hu F
Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2271-2283. PubMed ID: 34013453
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
6. Lascufloxacin hydrochloride to treat bacterial infection.
Thakare R; Singh S; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Jun; 56(6):365-376. PubMed ID: 32525135
[TBL] [Abstract][Full Text] [Related]
7. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
Tantisiriwat W; Linasmita P
J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
9. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
10. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
13. Clinical studies of garenoxacin.
Takagi H; Tanaka K; Tsuda H; Kobayashi H
Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of sitafloxacin against atypical bacteria (2009-2014) and comparison between susceptibility of clinical isolates in 2009 and 2012.
Amano A; Kishi N; Koyama H; Matsuzaki K; Matsumoto S; Uchino K; Yamaguchi H; Yokomizo A; Mizuno M
Jpn J Antibiot; 2016 Sep; 69(3):131-142. PubMed ID: 30226949
[TBL] [Abstract][Full Text] [Related]
15. [Clinical position of sitafloxacin in outpatient chemotherapy. (discussion)].
Niki Y; Aoki N; Suzuki K; Matsumoto T
Jpn J Antibiot; 2009 Jun; 62(3):179-93. PubMed ID: 19882979
[No Abstract] [Full Text] [Related]
16. Prulifloxacin.
Keam SJ; Perry CM
Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
[TBL] [Abstract][Full Text] [Related]
17. A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
Li Y; Yin Y; Peng X; Zheng H; Fu F; Liu Z; Wu X; Wu X; Zheng S; Chen N; He L; Ren L; Ni Z; Li D; Liang P; Lv X; Zhang Y
Ann Med; 2021 Dec; 53(1):217-226. PubMed ID: 33331182
[TBL] [Abstract][Full Text] [Related]
18. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
20. Gemifloxacin: a new fluoroquinolone.
Blondeau JM; Missaghi B
Expert Opin Pharmacother; 2004 May; 5(5):1117-52. PubMed ID: 15155113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
